Safety, Tolerability and Preliminary Efficacy of Unilateral Latanoprost-loaded Punctual Plug -EXP-LP
Status:
Unknown status
Trial end date:
2019-09-01
Target enrollment:
Participant gender:
Summary
Glaucoma is the most frequent cause of irreversible & preventable blindness worldwide,
affecting about 2% of the world's population in people over 40. The major risk factor, and
only treatable factor in glaucoma, is increased intraocular pressure (IOP). IOP reduction can
slow or arrest the progression of vision loss.
Current treatment consists of drops administered on a daily basis with unfortunately low
patient compliance, increasing the chance of blindness.
Eximore's product aims to eliminate the need to apply eye drops on a daily basis and thus
solves the significant problem of patient compliance.